Analysed ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) News Sources
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
31-03-2026
yahoo.com
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased
19-03-2026
marketbeat.com
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
25-02-2026
yahoo.com
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
24-02-2026
yahoo.com
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
21-10-2025
yahoo.com
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
02-09-2025
yahoo.com
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
11-08-2025
yahoo.com
What is the current price of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?
The current price of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is $0.82.
ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) since the previous trading day is $0.025.
ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) since the previous trading day is 3.1447%.
What is the most recent average sentiment score for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?
The most recent average sentiment score for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?
The most recent sentiment for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is .
SEC-8K** Filing Available For ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.